|
Malignant neoplasm of pancreas
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, CRMP4 protein levels in primary tumors of pancreatic cancer (n = 53) were examined by immunohistochemistry and compared with the clinicopathological features of the tumors.
|
22805864 |
2013 |
|
Malignant neoplasm of pancreas
|
0.020 |
Biomarker
|
disease |
BEFREE |
Understanding the mechanisms of CRMP4 would help us to develop novel therapeutic strategies against acute or chronic pancreatitis, and pancreatic cancer.
|
27207309 |
2016 |
|
Malignant neoplasm of prostate
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
There are two transcriptional variants of DPYSL3 gene in human genome, of which the variant 2 is the dominant transcript (DPYSL3v2, CRMP4a) but is also significantly down-regulated in primary prostate cancers.
|
27014974 |
2016 |
|
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
This proof-of-concept study with dTALEs for locus-specific epigenomic manipulation validates the selected CpG methylation of CRMP4 gene as an independent biomarker for diagnosis and prognosis of prostate cancer metastasis and opens up a novel avenue for mechanistic research on cancer biology.
|
25888628 |
2015 |
|
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
Taken together, our research indicated CRMP4 inhibits prostate cancer cells growth in the nude mouse bone microenvironment and this effect may relate with regulation of NRP1 and Noggin expression.
|
25338524 |
2015 |
|
Malignant neoplasm of prostate
|
0.080 |
PosttranslationalModification
|
disease |
BEFREE |
We then focused on the cooperative crosstalk of calpain-2 and NF-κB RelA/p65 in CRMP4 promoter methylation for the initiation of PCa metastasis.
|
29601651 |
2018 |
|
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data demonstrated that saRNA-based DPYSL3 gene enhancement is capable of suppressing tumor metastasis in prostate cancer, which provides a potential therapeutic approach for cancer management.
|
28639202 |
2019 |
|
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
CRMP4 promoter methylation in diagnostic biopsies could be a robust biomarker for LNM in PCa.
|
28122909 |
2017 |
|
Malignant neoplasm of prostate
|
0.080 |
PosttranslationalModification
|
disease |
BEFREE |
Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients.
|
28382925 |
2019 |
|
Malignant neoplasm of prostate
|
0.080 |
Biomarker
|
disease |
BEFREE |
Thus, in this study, we show new function of CRMP4 as a metastasis-suppressor in PCa.
|
20543870 |
2010 |
|
Malignant neoplasm of stomach
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
High DPYSL3 mRNA expression in GCs was significantly associated with more malignant phenotypes and was an independent prognostic factor.
|
25096402 |
2014 |
|
Malignant neoplasm of stomach
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The combination of serum ANOS1 and DPYSL3 levels increased the AUC value that discriminated patients with GC from healthy controls.
|
31377880 |
2020 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Dihydropyrimidinase-like 3 (DPYSL3) suppresses cell proliferation and tumorigenicity of certain malignancies; however, its role in HCC is unknown.
|
25173447 |
2015 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In conclusion, our data demonstrated that saRNA-based DPYSL3 gene enhancement is capable of suppressing tumor metastasis in prostate cancer, which provides a potential therapeutic approach for cancer management.
|
28639202 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
This proof-of-concept study with dTALEs for locus-specific epigenomic manipulation validates the selected CpG methylation of CRMP4 gene as an independent biomarker for diagnosis and prognosis of prostate cancer metastasis and opens up a novel avenue for mechanistic research on cancer biology.
|
25888628 |
2015 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Characterization of the roles of dihydropyrimidinase-like 3 in relation to cancer cell adhesion and migration in vitro, and metastasis in vivo was performed using a series of functional analyses, including those employing multiple reaction monitoring proteomic analysis.
|
24339867 |
2013 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
GC tissues from tumors with distant metastases (stage IV cancer) showed elevated expression levels of DPYSL3 mRNA.
|
25096402 |
2014 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis.
|
27014974 |
2016 |
|
Middle Cerebral Artery Occlusion
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, VEGF overexpression significantly increased cell proliferation in the ipsilateral SVZ and the numbers of BrdU(+)-CRMP-4(+) and BrdU(+)-Tuj1(+), two markers of immature newborn neurons, and BrdU(+)-MAP-2(+), a marker of mature newborn neurons, cells in the ipsilateral striatum to MCAO.
|
17061257 |
2007 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis.
|
27014974 |
2016 |
|
Neoplasm Metastasis
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients.
|
28382925 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, our data demonstrated that saRNA-based DPYSL3 gene enhancement is capable of suppressing tumor metastasis in prostate cancer, which provides a potential therapeutic approach for cancer management.
|
28639202 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Subsequent in vitro and in vivo studies revealed that overexpression of CRMP4 not only suppressed the invasion ability of PCa cells, but also strongly inhibited tumor metastasis in an animal model.
|
20543870 |
2010 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This proof-of-concept study with dTALEs for locus-specific epigenomic manipulation validates the selected CpG methylation of CRMP4 gene as an independent biomarker for diagnosis and prognosis of prostate cancer metastasis and opens up a novel avenue for mechanistic research on cancer biology.
|
25888628 |
2015 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Enhancing CRMP4 expression by promoter-targeted small activating RNAs reduced cell migration in vitro and abolished distal metastasis in mouse xenograft models.
|
30081723 |
2018 |